Analyst Rating Update on Halozyme Therapeutics (HALO)

Halozyme Therapeutics (NASDAQ:HALO) : 4 brokerage houses believe that Halozyme Therapeutics (NASDAQ:HALO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.6.

Halozyme Therapeutics (NASDAQ:HALO) : Average target price received by Halozyme Therapeutics (NASDAQ:HALO) is $12.58 with an expected standard deviation of $5.08. The most aggressive target on the stock is $16, whereas the most downbeat target is $7. 3 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.

Halozyme Therapeutics (NASDAQ:HALO): stock turned positive on Tuesday. Though the stock opened at $7.94, the bulls momentum made the stock top out at $8.18 level for the day. The stock recorded a low of $7.9133 and closed the trading day at $8.17, in the green by 5.01%. The total traded volume for the day was 1,475,826. The stock had closed at $7.78 in the previous days trading.

In an insider trading activity, Stelzer Laurie, CFO of Halozyme Therapeutics Inc, executed a transaction worth $172,400 on August 20, 2015. A total of 10,000 shares were purchased at an average price of $17.24. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *